Stay updated with breaking news from Otsuka Pharm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On August 22, 2023, the U.S. Court of Appeals for the Federal Circuit issued yet another decision reinforcing what can only be described as the “lead compound” rule for challenging pharmaceutical and other chemical compound patents on the basis of obviousness.
On August 22, 2023, the Federal Circuit issued a nonprecedential decision holding that claims directed to deuterated analogs of ruxolitinib were unpatentable as obvious. Sun Pharm....
On August 22, 2023, the Federal Circuit issued a nonprecedential decision holding that claims directed to deuterated analogs of ruxolitinib were unpatentable as obvious. Sun Pharm. Indus
ALKERMES PUBLIC LIMITED COMPANY DIRECTORS' REPORT AND CONSOLIDATED FINANCIAL STATEMENTS For the Financial Year Ended... | April 6, 2023
The so-called “Lead Compound Analysis” is the primary legal framework for assessing chemical obviousness. Despite the USPTO Patent Trial and Appeal Board’s (PTAB) initial apparent...